{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:21:45Z","timestamp":1781101305753,"version":"3.54.1"},"reference-count":55,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17lk0201043"],"award-info":[{"award-number":["JP17lk0201043"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K11617"],"award-info":[{"award-number":["JP20K11617"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>11\u03b2-hydroxysteroid dehydrogenase type 1 (11\u03b2-HSD1) inhibitors demonstrate antimetabolic and antisarcopenic effects in Cushing\u2019s syndrome (CS) and autonomous cortisol secretion (ACS) patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To confirm the efficacy and safety of S-707106 (11\u03b2-HSD1 inhibitor) administered to CS and ACS patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A 24-week single-center, open-label, single-arm, dose-escalation, investigator-initiated clinical trial on a database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Kyushu University Hospital, Kurume University Hospital, and related facilities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>Sixteen patients with inoperable or recurrent CS and ACS, with mildly impaired glucose tolerance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>Oral administration of 200 mg S-707106 after dinner, daily, for 24 weeks. In patients with insufficient improvement in oral glucose tolerance test results at 12 weeks, an escalated dose of S-707106 (200 mg twice daily) was administered for the residual 12 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>The rate of participants responding to glucose tolerance impairment, defined as those showing a 25% reduction in the area under the curve (AUC) of plasma glucose during the 75-g oral glucose tolerance test at 24 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>S-707106 administration could not achieve the primary endpoint of this clinical trial (&amp;gt;20% of responsive participants). AUC glucose decreased by \u22127.1% [SD, 14.8 (90% CI \u221214.8 to \u22121.0), P\u2005=\u20050.033] and \u22122.7% [14.5 (\u221210.2 to 3.4), P\u2005=\u20050.18] at 12 and 24 weeks, respectively. S-707106 administration decreased AUC glucose significantly in participants with a high body mass index. Body fat percentage decreased by \u22122.5% [1.7 (\u22123.3 to \u22121.8), P\u2005&amp;lt;\u20050.001] and body muscle percentage increased by 2.4% [1.6 (1.7 to 3.1), P\u2005&amp;lt;\u20050.001].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>S-707106 is an effective insulin sensitizer and antisarcopenic and antiobesity medication for these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab450","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T16:49:03Z","timestamp":1624034943000},"page":"e3865-e3880","source":"Crossref","is-referenced-by-count":35,"title":["An Open-label Phase I\/IIa Clinical Trial of 11\u03b2-HSD1 Inhibitor for Cushing\u2019s Syndrome and Autonomous Cortisol Secretion"],"prefix":"10.1210","volume":"106","author":[{"given":"Satoko","family":"Oda","sequence":"first","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8753-6016","authenticated-orcid":false,"given":"Kenji","family":"Ashida","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka-city, Japan"},{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Hasuzawa","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka-city, Japan"},{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Nagayama","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka-city, Japan"},{"name":"Department of Medical Biochemistry, Kurume University School of Medicine, Kurume-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Todaka","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0725-3161","authenticated-orcid":false,"given":"Masatoshi","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka-city, Japan"},{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"issue":"4","key":"2021110612095305500_CIT0001","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1210\/er.2012-1050","article-title":"11\u03b2-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects","volume":"34","author":"Gathercole","year":"2013","journal-title":"Endocr Rev."},{"issue":"10","key":"2021110612095305500_CIT0002","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1210\/en.2013-1362","article-title":"11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11\u03b2-HSD1 is knocked out in livers of male mice","volume":"154","author":"Harno","year":"2013","journal-title":"Endocrinology."},{"issue":"12","key":"2021110612095305500_CIT0003","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1210\/jc.2009-1412","article-title":"11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation","volume":"94","author":"Cooper","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021110612095305500_CIT0004","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1210\/jcem.86.3.7453","article-title":"Tissue-specific dysregulation of cortisol metabolism in human obesity","volume":"86","author":"Rask","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021110612095305500_CIT0005","first-page":"3330","article-title":"Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity","volume":"87","author":"Rask","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021110612095305500_CIT0006","doi-asserted-by":"crossref","first-page":"720","DOI":"10.2337\/db10-0726","article-title":"Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition","volume":"60","author":"Stimson","year":"2011","journal-title":"Diabetes."},{"issue":"56","key":"2021110612095305500_CIT0007","doi-asserted-by":"crossref","first-page":"96263","DOI":"10.18632\/oncotarget.22015","article-title":"11\u03b2-HSD1 inhibition ameliorates diabetes-induced cardiomyocyte hypertrophy and cardiac fibrosis through modulation of EGFR activity","volume":"8","author":"Zou","year":"2017","journal-title":"Oncotarget."},{"issue":"1","key":"2021110612095305500_CIT0008","doi-asserted-by":"crossref","first-page":"e000063","DOI":"10.1136\/bmjophth-2016-000063","article-title":"Oral administration of the 11\u03b2-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study","volume":"1","author":"Schwab","year":"2017","journal-title":"BMJ Open Ophthalmol."},{"issue":"1","key":"2021110612095305500_CIT0009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/cen.13889","article-title":"Glucocorticoid activation by 11\u03b2-hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: a cross-sectional study","volume":"90","author":"Sagmeister","year":"2019","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"3","key":"2021110612095305500_CIT0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.febslet.2006.11.032","article-title":"Augmentation of 11beta-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1 macrophages: role of 11beta-HSD1 in pro-inflammatory properties in macrophages","volume":"581","author":"Ishii","year":"2007","journal-title":"FEBS Lett."},{"issue":"4","key":"2021110612095305500_CIT0011","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/diabetes.53.4.931","article-title":"Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice","volume":"53","author":"Morton","year":"2004","journal-title":"Diabetes."},{"issue":"1","key":"2021110612095305500_CIT0012","first-page":"57","article-title":"Absence of Cushingoid phenotype in a patient with Cushing\u2019s disease due to defective cortisone to cortisol conversion","volume":"87","author":"Tomlinson","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021110612095305500_CIT0013","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1507\/endocrj.K08E-008","article-title":"A case of cortisol producing adrenal adenoma without phenotype of Cushing\u2019s syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 activity","volume":"55","author":"Arai","year":"2008","journal-title":"Endocr J."},{"issue":"5549","key":"2021110612095305500_CIT0014","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1126\/science.1066285","article-title":"A transgenic model of visceral obesity and the metabolic syndrome","volume":"294","author":"Masuzaki","year":"2001","journal-title":"Science."},{"issue":"1","key":"2021110612095305500_CIT0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1172\/JCI17845","article-title":"Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice","volume":"112","author":"Masuzaki","year":"2003","journal-title":"J Clin Invest."},{"issue":"7","key":"2021110612095305500_CIT0016","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.2337\/dc09-2315","article-title":"The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care."},{"key":"2021110612095305500_CIT0017","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/2050-6511-15-43","article-title":"A novel 11\u03b2-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6\/J mice with a potential to provide cardio protective benefits","volume":"15","author":"Anil","year":"2014","journal-title":"BMC Pharmacol Toxicol."},{"issue":"6","key":"2021110612095305500_CIT0018","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1463-1326.2011.01375.x","article-title":"Effects of an 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome","volume":"13","author":"Feig","year":"2011","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"2021110612095305500_CIT0019","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1210\/clinem\/dgaa766","article-title":"11\u03b2HSD1 inhibition with AZD4017 improves lipid profiles and lean muscle mass in idiopathic intracranial hypertension","volume":"106","author":"Hardy","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021110612095305500_CIT0020","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jash.2011.01.009","article-title":"Efficacy and safety of the selective 11\u03b2-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension","volume":"5","author":"Shah","year":"2011","journal-title":"J Am Soc Hypertens."},{"issue":"5","key":"2021110612095305500_CIT0021","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/dom.12635","article-title":"Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11\u03b2-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11\u03b2-HSD1 inhibition after acute and multiple administrations over 2\u2009weeks","volume":"18","author":"Freude","year":"2016","journal-title":"Diabetes Obes Metab."},{"key":"2021110612095305500_CIT0022","doi-asserted-by":"crossref","first-page":"S364","DOI":"10.1016\/j.jalz.2013.09.010","article-title":"Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer\u2019s disease","volume":"10","author":"Marek","year":"2014","journal-title":"Alzheimers Dement."},{"issue":"5","key":"2021110612095305500_CIT0023","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2213-8587(13)70170-0","article-title":"Inhibition of 11\u03b2-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Stefan","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"2021110612095305500_CIT0024","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/dom.12317","article-title":"Safety, efficacy and weight effect of two 11\u03b2-HSD1 inhibitors in metformin-treated patients with type 2 diabetes","volume":"16","author":"Heise","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"2021110612095305500_CIT0025","author":"Oda","year":"2011"},{"issue":"2","key":"2021110612095305500_CIT0026","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/JOE-19-0168","article-title":"Chronic hypercortisolism causes more persistent visceral adiposity than HFD-induced obesity","volume":"242","author":"Garc\u00eda-Eguren","year":"2019","journal-title":"J Endocrinol."},{"issue":"2","key":"2021110612095305500_CIT0027","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2021110612095305500_CIT0028","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4158\/DSCR-2018-0565","article-title":"The evaluation of incidentally discovered adrenal masses","volume":"25","author":"Vaidya","year":"2019","journal-title":"Endocr Pract."},{"issue":"11","key":"2021110612095305500_CIT0029","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1210\/jc.2001-011766","article-title":"Patients with subclinical Cushing\u2019s syndrome due to adrenal adenoma have increased cardiovascular risk","volume":"87","author":"Tauchmanov\u00e0","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021110612095305500_CIT0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1530\/EJE-17-0047","article-title":"Cardiovascular events in patients with mild autonomous cortisol secretion: analysis with artificial neural networks","volume":"177","author":"Morelli","year":"2017","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2021110612095305500_CIT0031","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"9522","key":"2021110612095305500_CIT0032","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","article-title":"Cushing\u2019s syndrome","volume":"367","author":"Newell-Price","year":"2006","journal-title":"Lancet."},{"issue":"5","key":"2021110612095305500_CIT0033","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021110612095305500_CIT0034","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1210\/jc.2010-2722","article-title":"Clinical review: diagnosis and treatment of subclinical hypercortisolism","volume":"96","author":"Chiodini","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021110612095305500_CIT0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1507\/endocrj.EJ17-0456","article-title":"New diagnostic criteria of adrenal subclinical Cushing\u2019s syndrome: opinion from the Japan Endocrine Society","volume":"65","author":"Yanase","year":"2018","journal-title":"Endocr J."},{"issue":"2","key":"2021110612095305500_CIT0036","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4239\/wjd.v1.i2.36","article-title":"Surrogate markers of insulin resistance: a review","volume":"1","author":"Singh","year":"2010","journal-title":"World J Diabetes."},{"issue":"5","key":"2021110612095305500_CIT0037","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-07-0762","article-title":"Evaluation of health-related quality of life in patients with Cushing\u2019s syndrome with a new questionnaire","volume":"158","author":"Webb","year":"2008","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2021110612095305500_CIT0038","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1530\/EJE-15-1237","article-title":"Mechanisms in endocrinology: tissue-specific activation of cortisol in Cushing\u2019s syndrome","volume":"175","author":"Morgan","year":"2016","journal-title":"Eur J Endocrinol."},{"issue":"1-2","key":"2021110612095305500_CIT0039","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.mce.2008.09.038","article-title":"Short-term glucocorticoid treatment increases insulin secretion in islets derived from lean mice through multiple pathways and mechanisms","volume":"301","author":"Hult","year":"2009","journal-title":"Mol Cell Endocrinol."},{"issue":"5","key":"2021110612095305500_CIT0040","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1210\/en.2009-1436","article-title":"Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse","volume":"151","author":"Karatsoreos","year":"2010","journal-title":"Endocrinology."},{"issue":"9","key":"2021110612095305500_CIT0041","first-page":"3082","article-title":"Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning","volume":"84","author":"Plat","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021110612095305500_CIT0042","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1210\/jc.2019-00420","article-title":"Glucocorticoid replacement affects serum adiponectin levels and HDL-C in patients with secondary adrenal insufficiency","volume":"104","author":"Hayashi","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021110612095305500_CIT0043","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cen.13902","article-title":"Changes of computed tomography-based body composition after adrenalectomy in patients with endogenous hypercortisolism","volume":"90","author":"Hong","year":"2019","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"3","key":"2021110612095305500_CIT0044","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1530\/JOE-16-0011","article-title":"Glucocorticoids and 11\u03b2-HSD1 are major regulators of intramyocellular protein metabolism","volume":"229","author":"Morgan","year":"2016","journal-title":"J Endocrinol."},{"issue":"7","key":"2021110612095305500_CIT0045","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1210\/jc.2015-1516","article-title":"Gender-specific differences in skeletal muscle 11\u03b2-HSD1 expression across healthy aging","volume":"100","author":"Hassan-Smith","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"49","key":"2021110612095305500_CIT0046","doi-asserted-by":"crossref","first-page":"E6780","DOI":"10.1073\/pnas.1512968112","article-title":"Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program","volume":"112","author":"Morrison-Nozik","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"2021110612095305500_CIT0047","first-page":"671","article-title":"A rodent model of rapid-onset diabetes induced by glucocorticoids and high-fat feeding","volume":"5","author":"Shpilberg","year":"2012","journal-title":"Dis Model Mech."},{"issue":"24","key":"2021110612095305500_CIT0048","doi-asserted-by":"crossref","first-page":"E2482","DOI":"10.1073\/pnas.1323681111","article-title":"11\u03b2-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess","volume":"111","author":"Morgan","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"11","key":"2021110612095305500_CIT0049","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1507\/endocrj.K10E-174","article-title":"Serum \u03b3-glutamyltransferase, triglyceride and total cholesterol are possible prediabetic risk markers in young Japanese men","volume":"57","author":"Akehi","year":"2010","journal-title":"Endocr J."},{"issue":"8","key":"2021110612095305500_CIT0050","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.metabol.2009.03.008","article-title":"Impact of metabolic syndrome on elevated serum alanine aminotransferase levels in the Japanese population","volume":"58","author":"Saito","year":"2009","journal-title":"Metabolism."},{"issue":"2","key":"2021110612095305500_CIT0051","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s12020-014-0388-6","article-title":"Steroid replacement in primary adrenal failure does not appear to affect circulating adipokines","volume":"48","author":"Fichna","year":"2015","journal-title":"Endocrine."},{"key":"2021110612095305500_CIT0052","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2020.00115","article-title":"Metabolic profiling reveals an abnormal pattern of serum fatty acids in MRL\/lpr mice under treatment with prednisone","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharmacol."},{"issue":"3","key":"2021110612095305500_CIT0053","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S8756-3282(00)00344-6","article-title":"Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone","volume":"27","author":"Cooper","year":"2000","journal-title":"Bone."},{"issue":"6","key":"2021110612095305500_CIT0054","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1210\/jc.2004-1375","article-title":"Quality of life in patients after long-term biochemical cure of Cushing\u2019s disease","volume":"90","author":"van Aken","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"17","key":"2021110612095305500_CIT0055","doi-asserted-by":"crossref","first-page":"E4091","DOI":"10.1073\/pnas.1714239115","article-title":"Ultradian rhythmicity of plasma cortisol is necessary for normal emotional and cognitive responses in man","volume":"115","author":"Kalafatakis","year":"2018","journal-title":"Proc Natl Acad Sci U S A."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab450\/39354222\/dgab450.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/10\/e3865\/41098052\/dgab450.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/10\/e3865\/41098052\/dgab450.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T12:12:10Z","timestamp":1636200730000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/10\/e3865\/6304789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,6,18]]},"published-print":{"date-parts":[[2021,9,27]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab450","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,6,18]]}}}